The call highlighted strong revenue growth and market adoption for PEDMARK, supported by strategic expansions and new accounts. However, increased operating expenses and dependency on market expansion present challenges. The momentum in PEDMARK's adoption and international expansion efforts suggest positive future prospects.

Company Guidance -

Q3 2025

During Fennec Pharmaceuticals' Second Quarter 2025 Earnings Call, the company provided optimistic guidance reflecting a strong growth trajectory. Revenue for the quarter reached $9.7 million, marking a 33% year-over-year increase and a 10% sequential growth, underscoring three consecutive quarters of growth. The company added 14 new accounts, signaling expanding adoption of PEDMARK, a therapy for preventing cisplatin-induced ototoxicity (CIO). CEO Jeff Hackman highlighted significant progress in awareness campaigns and payer-provider access, which are expected to drive future growth. Additionally, Fennec's partnership with Norgine in the EU, particularly in the UK and Germany, showed promising traction, with expectations of further milestones and royalty revenues. Operating expenses for the quarter were approximately $11 million, with a focus on marketing and intellectual property, and the company projected full-year operating expenses to align with the previous year’s $33 million. Overall, Fennec remains confident in achieving continued revenue growth and progressing towards cash profitability.

PEDMARK Revenue Growth

Revenue grew 33% year-over-year and 10% sequentially with net revenues of $9.7 million, marking the third consecutive quarter of growth.

Expanded Market Adoption

PEDMARK was added to the formulary of a large national oncology group for patients under 40, indicating broader market adoption.

Positive Quality Intervention Issued

NCODA issued a positive quality intervention (PQI) for PEDMARK, providing guidance to oncology care teams on its use.

International Expansion

PEDMARQSI launched in the UK and Germany, with further EU expansion planned, and positive traction reported.

New Accounts and Growth Strategy

Addition of 14 new accounts in Q2, including large community oncology groups, with continued activation expected in Q3.

Fennec Pharmaceuticals (TSE:FRX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TSE:FRX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	0.10 / -	-0.291	―	―	―
Aug 14, 2025	2025 (Q2)	-0.05 / -0.15	-0.274	44.53% (+0.12)	―
May 13, 2025	2025 (Q1)	-0.13 / -0.06	0.56	-110.00% (-0.62)	―
Mar 10, 2025	2024 (Q4)	-0.18 / -0.09	-0.135	35.56% (+0.05)	―
Nov 07, 2024	2024 (Q3)	-0.12 / -0.29	-0.096	-203.12% (-0.19)	―
Aug 13, 2024	2024 (Q2)	-0.03 / -0.27	-0.281	2.49% (<+0.01)	―
May 14, 2024	2024 (Q1)	-0.08 / 0.56	-0.31	280.65% (+0.87)	―
Mar 21, 2024	2023 (Q4)	-0.02 / -0.14	-0.352	61.65% (+0.22)	―
Nov 06, 2023	2023 (Q3)	-0.16 / -0.10	-0.411	76.64% (+0.31)	―
Aug 03, 2023	2023 (Q2)	-0.21 / -0.28	-0.243	-15.64% (-0.04)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TSE:FRX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 14, 2025	C$12.51	C$11.36	-9.19%
May 13, 2025	C$8.66	C$8.66	0.00%
Mar 10, 2025	C$9.82	C$8.81	-10.29%
Nov 07, 2024	C$6.86	C$6.08	-11.37%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Fennec Pharmaceuticals (TSE:FRX) report earnings?

Fennec Pharmaceuticals (TSE:FRX) is schdueled to report earning on Nov 06, 2025, TBA (Confirmed).

What is Fennec Pharmaceuticals (TSE:FRX) earnings time?

Fennec Pharmaceuticals (TSE:FRX) earnings time is at Nov 06, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is TSE:FRX EPS forecast?

TSE:FRX EPS forecast for the fiscal quarter 2025 (Q3) is 0.1.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing